ResearchAndMarkets.com released a comprehensive market report on China's sterilization equipment industry covering chemical, physical, and ultraviolet sterilizers. The report provides revenue, volume, and pricing data from 2018-2033, competitive analysis of major players, and strategic insights for market entry and expansion in this growing sector.

A comprehensive market report on China's patient examination devices market covering thermometers and stethoscopes through 2033. The report provides revenue, volume, and pricing data for medical device manufacturers, investors, and healthcare stakeholders, with 2025 company share analysis and competitive intelligence on key market players.

Solventum (SOLV), a medical services company, demonstrates a strong track record of beating earnings estimates, with an average surprise of 21.57% over the last two quarters. The company's positive Earnings ESP of +2.81% combined with its Zacks Rank #3 suggests another earnings beat is likely in the near term.

Solventum (SOLV), a healthcare company spun off from 3M, is highlighted as a stock to watch with a #3 (Hold) Zacks Rank and a VGM Score of B. The company features attractive valuation metrics with a forward P/E ratio of 11.9 and has seen upward earnings estimate revisions, with an average earnings surprise of +13.2%.

The article explains how to identify medical stocks poised for earnings surprises using the Zacks Earnings ESP (Expected Surprise Prediction) tool. It highlights that combining a positive ESP with a Zacks Rank #3 or better has historically produced 70% positive surprises and 28.3% average annual returns. Two medical stocks are featured as examples: Solventum (SOLV) with a +2.81% ESP and ANI Pharmaceuticals (ANIP) with a +6.45% ESP, both expected to report earnings in early November 2026.

Zacks highlights two medical stocks with positive Earnings Surprise Prediction (ESP): CVS Health and Solventum. Both stocks have positive ESP figures and are expected to report earnings in early November 2026, suggesting potential for earnings beats based on recent analyst revisions.

Zacks presents its Focus List, a curated portfolio of 50 stocks selected based on positive earnings estimate revisions. The list has historically outperformed the S&P 500, with cumulative returns of 2,519.23% since February 1996 compared to the S&P's 854.95%. The methodology relies on the Zacks Rank system, which evaluates stocks based on earnings consensus among analysts. Solventum (SOLV), a healthcare company spun off from 3M, is highlighted as a recent addition that has gained 29.89% since April 2024.

Solventum Corporation (SOLV), a healthcare company spun off from 3M, has been added to the Zacks Focus List. The stock has gained 31.53% since its April 2024 IPO at $69.15, now trading at $90.95. Six analysts raised earnings estimates in the last 60 days, with consensus estimates increasing $0.55 to $7.13 for fiscal 2026. The company is expected to deliver 16.7% earnings growth for the current fiscal year and has demonstrated a 13.2% average earnings surprise.

The global gauze bandage rolls market is valued at USD 1.96 billion in 2025 and is projected to reach USD 3.19 billion by 2035, growing at a CAGR of 4.97%. Growth is driven by rising surgical procedures, aging populations, chronic wound management, and technological advancements in antimicrobial and bioactive gauze products. Key market segments include cotton gauze (largest share), surgical wounds (dominant application), and hospitals (primary end-user), with Asia Pacific expected to show the fastest growth.

3M and UPS are both iconic industrial companies facing headwinds, but they present different investment cases. 3M has spun off its healthcare business and faces material legal liabilities from PFAS and military earplugs lawsuits, with valuations above five-year averages despite these risks. UPS is executing a turnaround strategy with upfront costs but showing signs of improvement, trading below five-year valuation averages with a much higher dividend yield. For most investors, particularly dividend seekers, UPS appears the better buy.

Clifford Capital Partners initiated a new position in WEX by acquiring 95,326 shares worth $14.20 million in the fourth quarter. WEX reported record revenue of $2.66 billion in 2025 with net income of $304.1 million, driven by strength in benefits and corporate payments segments. The stock has remained flat year-to-date despite the S&P 500's 20% gain.

Three technology and healthcare stocks - Keysight Technologies, Sea Ltd, and Solventum - have announced significant share buyback programs in 2025, demonstrating management confidence and potentially enhancing shareholder value.